Prescription digital therapeutics pioneer Pear Therapeutics announced today that it will go public by merging with a SPAC called Thimble Point Acquisition Corp. Boston-based Pear Therapeutics’ combination with the special purpose acquisition company (SPAC), whose management team is associated with the Pritzker Vlock Family Office, will result in a combined company named Pear Holdings Corp. […]
Glytec names Nausheen Moulana as chief technology officer
Cloud-based insulin management software developer Glytec announced today that it appointed Nausheen Moulana as its chief technology officer. In the role of CTO, Moulana will be responsible for Glytec’s product and technology vision, strategy and execution. She will lead the company’s product development teams — focusing on enhancements in provider workflows, electronic health record (EHR) […]
Smiths Medical recalls some insulin syringes over skewed graduation marking
Smiths Medical announced today that it issued recall notices for its Jelco Hypodermic Needle-Pro fixed needle insulin syringes. Minneapolis-based Smiths Medical became aware of specific models and lots of the Jelco Hypodermic Needle-Pro fixed needle syringes that may exhibit skewed odd number line graduation markings on their syringe barrels. The company identified markings skewed upward […]
Fractyl raises $100M for diabetes reversal tech, renamed as Fractyl Health
Fractyl Labs today announced the closing of a $100 million Series F financing round in addition to a name change to Fractyl Health. Lexington, Mass.-based Fractyl Health received contributions to the round from new investors Maverick Capital, M28 Capital and Population Health Partners, while other new and existing investors participated, too. According to a news […]
Diabetes Center Berne launches open innovation challenge for diabetes tech
The Diabetes Center Berne today announced the launch of an initiative to develop technology to address the treatment of diabetes. DCB is seeking innovators, co-creators, scientists and members of the diabetes community to join the company’s innovation challenge and join its community of diabetes technology developers. The center requested anyone ranging from members of start-ups, […]
MedinCell to begin regulatory development of long-acting injectable malaria treatment
MedinCell announced that its long-acting injectable malaria treatment is ready to enter into the stages of regulatory development. Montpellier, France–based MedinCell conducted an in vivo proof of concept on cattle that demonstrated three-month mosquitocidal effectiveness in the injectable, long-acting formulation of Ivermectin using the company’s BEPO delivery technology. The company designed the investigational mdc-STM product […]
FDA extends NDA review period for Incyte’s atopic dermatitis therapeutic cream
Incyte (NSDQ:INCY) announced today that the FDA extended the review period for the new drug application for its ruxolitinib cream. Wilmington, Del.-based Incyte designed its ruxolitinib cream to treat atopic dermatitis (AD). The company designed the proprietary formulation of its selective JAK1/JAK2 inhibitor ruxolitinib for topical application, according to a news release. Currently, the ruxolitinib […]
Cardinal Health wins new FDA approval for Lymphoseek
Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use. Dublin, Ohio-based Cardinal Health touts Lymphoseek — acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016 — as the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies (SLNB). The new indication will expand […]
Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant
Glaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant. San Clemente, Calif.–based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levels of the medication for […]
ViaCyte closes $45M financing for stem cell-derived type 1 diabetes therapies
ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its advanced portfolio of cell-derived therapies designed to provide a functional cure for patients […]
